Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
Alnylam将通过网络直播电话会议讨论2024年第二季度财务业绩
Jul 18, 2024
2024 年 7 月 18 日
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 18, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open.
马萨诸塞州剑桥--(美国商业资讯)--2024年7月18日--领先的RNAi治疗公司Alnylam Pharmicals, Inc.（纳斯达克股票代码：ALNY）今天宣布，将在美国金融市场开放之前，即2024年8月1日星期四公布截至2024年6月30日的第二季度财务业绩。
Management will provide an update on the Company and discuss second quarter 2024 results as well as expectations for the future via conference call on Thursday, August 1, 2024 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at . An archived webcast will be available on the Alnylam website approximately two hours after the event.
管理层将在美国东部时间2024年8月1日星期四上午 8:30 通过电话会议介绍公司的最新情况，讨论2024年第二季度的业绩以及对未来的预期。电话会议的网络直播将在公司网站的 “投资者” 部分播出，网址为。活动结束大约两小时后，将在Alnylam网站上提供存档的网络直播。
About Alnylam Pharmaceuticals
关于 Alnylam 制药
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or on Instagram.
Alnylam（纳斯达克股票代码：ALNY）领导了将RNA干扰（RNAi）转化为一种全新的创新药物，有可能改变患有罕见和流行病但需求未得到满足的人们的生活。基于诺贝尔奖得主的科学，RNAi疗法代表了一种强大的、经过临床验证的方法，可以产生革命性的药物。自2002年成立以来，Alnylam一直领导着RNAi革命，并继续实现将科学可能性变为现实的大胆愿景。Alnylam的商用RNAi治疗产品是ONPATTRO（patisiran）、AMVUTTRA（vutrisiran）、GIVLAARI（givosiran）、OXLUMO（lumasiran）和Leqvio（inclisiran），后者由Alnylam的合作伙伴诺华开发和商业化。Alnylam拥有大量在研药物，包括多种处于后期开发阶段的候选产品。Alnylam正在执行其 “Alnylam P5x25” 战略，通过可持续创新和卓越的财务业绩，提供针对罕见和常见疾病的变革性药物，使全球患者受益，从而形成领先的生物技术地位。Alnylam总部位于马萨诸塞州剑桥。如需了解有关我们的员工、科学和渠道的更多信息，请通过 X（前身为 Twitter）@Alnylam、LinkedIn 或 Instagram 访问并与我们互动。
View source version on businesswire.com:
在 businesswire.com 上查看源版本：
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Alnylam 制药公司
克里斯汀·里根·林登布姆
（投资者和媒体）
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
乔什·布罗德斯基
（投资者）
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
来源：Alnylam Pharmicals, Inc.